COMMUNIQUÉS West-GlobeNewswire

CytoDyn Announces First Patient Dosed in Expanded Access Program for Leronlimab in Triple-Negative Breast Cancer
27/04/2026
Program provides access to leronlimab for patients with limited treatment options while supporting ongoing clinical development VANCOUVER, Washington, April 27, 2026 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) (" [...]
Apollomics Reports Full Year 2025 Financial Results and Provides Clinical Updates and Business Progress
27/04/2026
Phase 2 studies ongoing to advance global development of vebreltinib, a highly potent, de-risked and differentiated c-MET Inhibitor with best-in-class and first-in-class potential. To date, more than 600 patients and [...]
SBC Medical Announces Full-Scale Rollout of Aesthetic Healthcare-Focused Interpretation App "Talk Bridge" Across All Shonan Beauty Clinic Locations
27/04/2026
Strengthening English-Speaking Customer Experience Through Interpretation Infrastructure, Specialized Talent, and Digital Marketing IRVINE, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- SBC Medical Group Holdings [...]
Opus Genetics to Participate in Leading Medical Conferences in May 2026
27/04/2026
RESEARCH TRIANGLE PARK, N.C., April 27, 2026 (GLOBE NEWSWIRE) -- Opus Genetics (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and [...]
Exagen Inc. to Announce First Quarter Financial Results on May 11, 2026
27/04/2026
CARLSBAD, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing, will release financial results for the quarter ended March 31, 2026, before the market [...]
Alpha Tau Announces Presentation of Pancreatic Cancer Data at Upcoming ASCO Annual Meeting, Showcasing Combined Results from Three Alpha DaRT Pancreatic Cancer Studies
27/04/2026
- Abstract accepted at the American Society of Clinical Oncology (ASCO) Annual Meeting - the world’s largest and most prestigious medical oncology conference - - Pooled analysis combines safety and efficacy data from 58 [...]
Humacyte to Host Virtual KOL Event to Discuss ATEV for Arteriovenous (AV) Access for Hemodialysis Patients on April 28, 2026
27/04/2026
DURHAM, N.C., April 27, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, [...]
Ardelyx Announces Abstract Accepted for Poster Presentation at the NKF’s Spring Clinical Meetings
27/04/2026
Presentation evaluates the long-term impact of XPHOZAH® on serum electrolytes and select nutrition biomarkers WALTHAM, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a commercial-stage [...]
NEXGEL Appoints Ian Blackman as Chief Financial Officer
27/04/2026
Veteran Financial and M&A Leader Appointed to Integrate Acquisition of Celularity, Scale the Business and Accelerate Growth LANGHORNE, Pa., April 27, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company [...]
Iovance Biotherapeutics to Report First Quarter 2026 Financial Results and Corporate Updates on Thursday, May 7, 2026
27/04/2026
SAN CARLOS, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating [...]
PharmAla Executes Binding Letter of Intent for Formation of Special Purpose Vehicle to Develop Patented Novel MDXX Molecule APA-01
27/04/2026
Definitive Agreement Targeted for Execution by June 2026 TORONTO, April 27, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (CSE: MDMA)(OTCQB: MDXXF) (“PharmAla” or the “Company”), a biotechnology company [...]
Vystar Plans Dividend Spin Off of RXAIR and Related Brands Following R3alm, Inc. Transaction
27/04/2026
Vystar Announces Strategic Direction for Vytex, FEC, and RXAIR BOSTON, MA, April 27, 2026 (GLOBE NEWSWIRE) -- Vystar Corporation (OTCQB: VYST) is focusing the majority of its resources on R3alm.com , which, is building [...]
Replimune to Present at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
27/04/2026
WOBURN, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced multiple [...]
TerrAscend Announces Preliminary First Quarter 2026 Financial Results and Schedules Earnings Conference Call
27/04/2026
First Quarter 2026 Net Revenue Totaled $65.5 million with Gross Profit Margin of 52.8% TORONTO, April 27, 2026 (GLOBE NEWSWIRE) -- TerrAscend Corp. ("TerrAscend" or the "Company") (TSX: TSND) (OTCQX: TSNDF) , a leading [...]
Siren Biotechnology Publishes Foundational AAV Immuno-Gene Therapy Data and Announces Presentations at ASGCT 2026
27/04/2026
SAN FRANCISCO, April 27, 2026 (GLOBE NEWSWIRE) -- Siren Biotechnology today announced the publication of its first peer-reviewed manuscript in Molecular Therapy Oncology , alongside upcoming presentations at the [...]
VVT Med Signs Largest European Distribution Agreement to Date; Distributor Joins as Investor
27/04/2026
Five-Year Agreement Represents Approximately CAD $2.3 Million in Minimum Purchase Commitments | Distributor Joins as Investor in the Company’s Ongoing Private Placement VANCOUVER, BC, April 27, 2026 (GLOBE NEWSWIRE) -- [...]
Akari Therapeutics Secures Australian Patent Approval, Further Expanding Global Protection of Its Proprietary PH1 RNA Splicing Modulator ADC Payload
27/04/2026
Patent covers proprietary 2nd generation Thailanstatin analog payload designed for use in ADCs (antibody-drug conjugates) targeting cancer Approval strengthens Akari’s global intellectual property across all major [...]
Oncolytics Aligns with FDA on Planned Pivotal Anal Cancer Study
27/04/2026
Company to leverage strong durability and survival data in second-line and later metastatic squamous cell anal carcinoma Pivotal study expected to focus on patients in a post-standard-of-care patient population with no [...]
Adial Pharmaceuticals Submits Application to FDA Commissioner’s National Priority Voucher (CNPV) Pilot Program for AD04 Clinical Development Program
27/04/2026
Voucher application details focus on AUD as a major driver of the U.S. substance use crisis and the genetic targeting of AD04’s role in providing a treatment option for patients where existing treatments inadequately [...]

Pages